Brainsway Ltd. (Brainsway) is a medical device company that develops and markets transcranial magnetic stimulation systems and noninvasive medical device for treatment of neurological and psychopathological disorders. The company offers deep transcranial magnetic stimulation products. Its deep TMS is used for treatment of depressive episodes in adult patients suffering from depressive disorder. Brainsway runs various clinical research programs. The company also operates online portals for patients, physicians and researchers. It collaborates with various institutions and researchers in clinical trials covering various neuropsychiatric and neuroscience applications. Brainsway is headquartered in Jerusalem, Israel.
The transcranial magnetic stimulator (TMS) market is projected to reach US$ 2,029.71 million by 2028 from US$ 1,122.22 million in 2021; it is expected to register a CAGR of 8.8% from 2021 to 2028. Neurological disorders affect the brain and nerves of the human body and cause epilepsy and seizures, Parkinson's disease, dementia, autism, Alzheimer's disease, brain tumors, and cerebral palsy, among others. The prevalence of neurological disorders is increasing across the world.
The Business Research Company offers transcranial magnetic stimulator market research report 2023 with industry size, share, segments and market growth
According to our latest study on “Transcranial Magnetic Stimulator (TMS) Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Age Group, and Application,” the market is projected to reach US$ 2,029.71 million by 2028 from US$ 1,122.22 million in 2021; it is expected to register a CAGR of 8.8% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.